

NBER WORKING PAPER SERIES

LAGGED-PRICE REIMBURSEMENT CONTRACTS:
THE IMPACT OF MEDICARE PART B ON PHARMACEUTICAL PRICE GROWTH

Angelique Acquatella
Keith Marzilli Ericson
Amanda Starc

Working Paper 31834
<http://www.nber.org/papers/w31834>

NATIONAL BUREAU OF ECONOMIC RESEARCH
1050 Massachusetts Avenue
Cambridge, MA 02138
November 2023

The authors gratefully acknowledge research support by grants from the NIHCM and NIA grant P30AG012810. We thank Mohan Ramanujan and Elizabeth Adams for their assistance obtaining and managing the data. We thank Taylor Watson for excellent research assistance. We thank Rena Conti, David Ridley, and seminar participants at Boston University, Indiana University, ASHEcon, and the Highland Health Economics Symposium for helpful comments. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.

At least one co-author has disclosed additional relationships of potential relevance for this research. Further information is available online at <http://www.nber.org/papers/w31834>

NBER working papers are circulated for discussion and comment purposes. They have not been peer-reviewed or been subject to the review by the NBER Board of Directors that accompanies official NBER publications.

© 2023 by Angelique Acquatella, Keith Marzilli Ericson, and Amanda Starc. All rights reserved. Short sections of text, not to exceed two paragraphs, may be quoted without explicit permission provided that full credit, including © notice, is given to the source.

Lagged-Price Reimbursement Contracts: The Impact of Medicare Part B on Pharmaceutical Price Growth

Angelique Acquatella, Keith Marzilli Ericson, and Amanda Starc

NBER Working Paper No. 31834

November 2023

JEL No. H57,I11

ABSTRACT

We examine cost-plus lagged-price reimbursement contracts, focusing on Medicare Part B's payment for physician-administered drugs. Our theoretical model shows that lagged-price reimbursement can raise launch prices but lower prices in later periods. While previous research showed Part B increased launch prices, we estimate its effect on later prices (net of rebates). Drugs more exposed to Medicare have lower price growth. A drug with above median Part B exposure has a 10% lower price after 3 years than a below median exposure drug that launched at the same price, with a larger effect for newly approved molecules.

Angelique Acquatella
Toulouse School of Economics
angelique.acquatella@tse-fr.eu

Keith Marzilli Ericson
Boston University
Questrom School of Business
595 Commonwealth Avenue
Boston, MA 02215
and NBER
kericson@bu.edu

Amanda Starc
Kellogg School of Management
Northwestern University
2211 Campus Drive
Evanston, IL 60208
and NBER
amanda.starc@kellogg.northwestern.edu

1 Introduction

Governments purchase goods and services from private firms ranging from defense contractors to healthcare providers. When contracting with the government, prices are rarely determined by a market mechanism, which can lead to distortions. In an efficient market, prices signal firm production costs and consumers' willingness to pay. Absent such an information aggregating mechanism, governments frequently use cost-plus contracts. Absent good information on costs, the government may use proxies, including past prices. The combination of cost-plus contracting and dynamic incentives can amplify or dampen distortions, especially when firms price strategically: the input price set by the firm today will affect the future reimbursement that contractors buying these inputs will receive from the payer.

This paper characterizes the effects of lagged-price cost-plus reimbursement on dynamic incentives for price setting, both theoretically and empirically. We focus on physician-administered drugs covered by Medicare Part B, which include anti-cancer/chemotherapy drugs and immunosuppressives. Payment for prescription drugs is particularly controversial, as the government (via Medicare) is a major purchaser from pharmaceutical firms who often hold a monopoly on the drug. In Medicare Part B, which covers physician-administered drugs, the government pays physicians using cost-plus reimbursement based on lagged-prices. However, widespread concern about rising drug prices has driven proposals to change how drugs are paid for and recent policy reforms in which government will directly negotiate drug prices.¹ Moreover, in addition to affecting drug spending, Part B policy could have important consequences for enrollee health. Medicare is a major payer for cancer care in the US, and Part B drugs are a major source of revenue for oncology practices.

Part B has a buy-and-bill policy, in which physicians purchase drugs (either on their own, or as part of a group purchasing organization). Medicare pays physicians when they deliver these drugs based on lagged average cost (from two quarters ago) plus a percentage markup. The policy has different incentives than either a simple fixed price or cost-plus contract (see Bajari and Tadelis (2001)). In particular, since physician margin is increasing in lagged-price, higher prices may ultimately lead physicians to prescribe *more*. While the introduction of the current Part B payment policy has been linked to higher drug prices at launch (Howard et al. 2015; Ridley and Lee 2020), it is unknown how Part B affects changes in prices over time.

¹In addition to the 2022 Inflation Reduction Act, e.g. as discussed in Cutler (2022), potential policy reforms are discussed in Ridley and Zhang (2017); Dubois et al. (2022); Ginsburg and Lieberman (2021). Lakdawalla (2018) provides a review of the literature on the economics of pharmaceuticals. By contrast, in Medicare Part D, which covers most self-administered drugs, the government has largely devolved price negotiation to private firms that offer insurance plans.

We first model the key features of Medicare payment for physician-administered drugs: pharmaceutical firms set prices, physicians buy the drug on behalf of patients and choose how much to consume, and Medicare reimburses physicians based on lagged market average prices. However, the structure of the model is relevant for other markets as well. For instance, in construction contracting, a producer sets a price for a construction-related input (e.g. asphalt), a construction contractor purchases that input, and the government makes additional payments to contractors if they have an economic price adjustment clause if an index of prices is higher than forecasted.²

In our theoretical model, pharmaceutical firms account for changes in future reimbursement when setting prices. Physician demand is affected by both current price and reimbursement, the difference between which is their margin. But because reimbursement levels affect not only physician reimbursement but patients’ level of cost-sharing, the model allows price and reimbursement to have different impacts on demand. We show that lagged-price cost-plus reimbursement, as implemented in Part B, can have an ambiguous effect on both initial prices and changes in prices over time. We show conditions under which it raises initial prices but also leads pharmaceutical firms to lower prices relative to launch in later periods. This pattern contrasts to common “invest-then-harvest” pricing (e.g. Farrell and Shapiro (1988); Ericson (2014)).

We then empirically examine how Part B’s payment policy affects prices changes over time during the period 2006-2019. We observe average prices net of rebates. Our identifying variation comes from drugs that are more or less exposed to Part B: the share of expenditures for a drug that comes via Medicare Part B, as opposed to private insurers. A similar research design is used by Yurukoglu et al. (2017) to show that exposure to Part B led to shortages in the generic market.³ Our identification strategy includes a drug fixed effect, so it does not rely on Medicare market share not being correlated with drug value or demand.

For a drug whose Medicare market share at launch is above the median, we estimate that prices 3 years after launch are at least 10% lower than a drug with below median exposure that launched at the same price, with a larger effect for newly approved molecules. Previous literature shows that physician-administered drug prices at launch have been increasing over time ((Howard et al. 2015) on anti-cancer drugs), and changes to Part B reimbursement in 2006 led to higher launch prices (Ridley and Lee 2020). We show that, following launch,

²See economic price adjustment clauses in construction and defense contracts discussed in Crocker and Reynolds (1993) and Kosmopoulou and Zhou (2014).

³Duggan and Scott Morton (2010) also use this strategy to show that the introduction of Medicare Part D *lowered* the cost of covered drugs, as plan formularies made the demand of newly insured individuals more elastic. Ippolito and Levy (2023) also show that drugs more exposed to Medicare Part D have larger differences between net and list prices of drugs.

more exposure to Part B payment led to slower price growth. We further document that the dynamic impact dampens but likely does not erase the overall upward pressure on prices generated by the Medicare program.

Our paper is related to a large literature that explores the impact of contracting and procurement rules in healthcare (e.g. Gaynor et al. (2023); Decarolis (2015)), construction (e.g. Bosio et al. (2022); Krasnokutskaya and Seim (2011)), and telecommunications (e.g. Kang and Miller (2022)). However, many of these papers do not examine the effects on how prices evolve over time (for an exception, see Ji and Rogers (2023)). Our paper examines these dynamic forces theoretically and empirically.

2 Institutional Setting

The Medicare program provides health insurance to elderly and disabled individuals in the United States. Part B covers outpatient care, including drugs administered by physicians. The majority of Part B drug payments are for services rendered in physician office settings; Part D covers outpatient drugs. Spending on Medicare Part B drugs totaled \$37.1 billion in 2019, which is about one-fifth the size of spending on Part D drugs. (MedPAC 2022). The top ten drugs ranked by Medicare Part B expenditures constitute about 40% of Part B drug spending. Since 2005, Medicare has reimbursed providers based on average sales price (ASP) (Jacobson et al. 2010; Yurukoglu et al. 2017; Ridley and Lee 2020).

The provider pays a price to the manufacturer that is averaged to construct an average sales price (ASP). The provider is then typically reimbursed at lagged ASP times a multiplier, here 106% the ASP from two quarters ago.⁴ The out-of-pocket costs for the patient are 20% of the reimbursed amount in the form of coinsurance; the Medicare program covers the remaining 80%.⁵ Initial period reimbursement cannot rely on lagged-prices, and is set at a markup over the “list” price, either Wholesale Average Cost (WAC)+6% or Average Wholesale Price (AWP) -5%. WAC is a list price reported by hospitals for drugs acquired through drug wholesalers. AWP is also a list price, reported by drug wholesalers. As noted by Ridley and Lee (2020), list prices at launch may be artificially high in these markets.

The Part B reimbursement system is controversial for several reasons. First, it is difficult for any administered price system to capture marginal costs. While some worry about overpayment, particularly for biologics (Morton and Boller 2017), others note that government policy can put a financial strain on providers (Polite et al. 2015). Lagged-price reimburse-

⁴The controversial 340B program allows some providers treating low-income patients to buy at a discount and (in some time periods) receive lower reimbursement. See Desai and McWilliams (2018).

⁵Patient cost-sharing is substantially reduced if they purchase additional Medigap insurance or are dual-eligible for Medicaid.

ment will additionally create dynamic pricing incentives that may affect provider treatment decisions and the lifetime profitability of drugs. For some physicians, reimbursements for these drugs constitute a substantial share of revenue. Financial incentives for physicians may be particularly strong in oncology because average drug margins for chemotherapy can range anywhere from a few cents to \$2,000 for a single dose. Physicians might have a preference for drugs with higher price levels, in so far as these yield a higher margin.

Medicare uses “J-codes” to identify injectable drugs, the majority of which (62%) have a monopoly manufacturer. For simplicity, we will model the pricing decisions of a monopolist.

3 Model

We develop a model of monopolist pricing under lagged-price reimbursement. In the model, some drug purchases are reimbursed by the government with lagged-price reimbursement, and the remainder are reimbursed by private insurers at an independently determined rate. We develop comparative statics for how price changes when the payer using lagged-price reimbursement comprises a larger versus smaller part of a drug’s market share.

3.1 Demand

Consider a two period ($t = 1, 2$) model of pharmaceutical pricing.⁶ Physicians acquire drugs directly from a pharmaceutical firm each period, and pharmaceutical firms set prices. Physicians then receive payment for the drug purchases from the government using lagged-price reimbursement. Private firms use their own independent payment methodology, which is determined outside the model.

Drug demand depends on physician utility, which consists of both profits and (potentially) patient well-being. Physicians make a binary decision of whether to prescribe a drug to each patient, and the utility of administering a drug to patient i in time period t is:

$$V_{it} = \underbrace{(r_t - p_t)}_{\text{physician profits}} + \tilde{\lambda} \underbrace{(h_{it} - oop(r_t))}_{\text{patient utility}}$$

where r_t is the reimbursement received by the physician, p_t is the price the physician pays to acquire the drug, $\tilde{\lambda}$ is the physician’s weight on patient utility, h_{it} the health benefit from administering the drug to patient i , and $oop(r_t)$ is the patient out-of-pocket cost, which can depend on reimbursement levels. The physician’s drug choice therefore depends on

⁶This can be generalized to multiple periods but two periods suffices to show the dynamics.

reimbursement, acquisition price, and a stochastic patient component. Define the physician's effective margin in period t as the difference between the weighted reimbursement and the price: $m_t \equiv \lambda r_t - p_t$, where reimbursement is weighted by $\lambda \equiv (1 - \tilde{\lambda} \frac{oop(r_t)}{r_t})$.

Quantity demanded is thus a function of the physician's *effective margin*, where λ is a weight that discounts the reimbursement based on disutility of patient cost-sharing. The demand function for a particular drug can be written as $Q(m_t)$, where total demand is the sum across patients i : $Q(m_t) \equiv \sum_i [\mathbf{P}(m_t + \tilde{\lambda} h_{it}) > 0]$. Demand is increasing in the effective margin ($Q'(m_t) \geq 0$). The effective margin is increasing in reimbursement so long as $\lambda > 0$, which requires the weight placed on physicians' own reimbursement to outweigh any disutility from higher patient cost-sharing.

3.2 Lagged-Price Reimbursement and Private Insurance

Expected reimbursement, r_t , is a linear combination of the Medicare rate and the private insurance rate, weighted by the Medicare market share of sales.⁷ When $t > 1$, the Medicare reimbursement rate is a function of the previous period price times a multiplier $(1 + A)$ and is given by $(1 + A)p_{t-1}$ with $A > 0$. Private reimbursement may follow Medicare to some extent. We assume it is at least partially independent (e.g. paying based on value or negotiated prices). See Theoretical Appendix for more detail. Let ρ_t be the private sector's independent component of price setting, which is determined outside the model.

Reimbursement in periods $t > 1$ is then a function of the effective Medicare market share s , which yields

$$r_t = s \cdot \underbrace{(1 + A)p_{t-1}}_{\text{Medicare reimbursement rate}} + (1 - s) \cdot \underbrace{\rho_t}_{\text{private insurance rate}} \quad (1)$$

Given that our focus is on the dynamic incentives created by lagged-price reimbursement, we make two simplifying assumptions about private reimbursement and initial period reimbursement. First, we assume private reimbursement stays constant over time, which allows us to isolate the pricing dynamics created by lagged-price reimbursement from other confounding forces that affect prices; that is, $\rho_t = \rho$.

Because our aim is to characterize the dynamic incentives associated with lagged-price reimbursement, we fix Medicare's launch reimbursement at the private insurance rate; that is, $r_1^M = \rho$. Our model is not designed to pin down Medicare's initial reimbursement, which

⁷We assume that physicians do not tailor their drug choice to the insurance status of the patient, though this is not consequential.

can be more or less generous than private reimbursement, and might vary by drug.

3.3 Price Setting

We now consider a pharmaceutical firm choosing prices for its drug to maximize profits. The pharmaceutical firm chooses a vector of prices $\mathbf{p} = \{p_1, p_2\}$ to maximize:

$$\Pi = \pi(p_1; r_1) + \delta\pi(p_2; r_2(p_1)) + \delta^2 EV(p_2)$$

where c is a constant marginal cost, $\pi(p_t; r_t) = Q(m_t)(p_t - c)$ are flow profits, and the term $EV(p_2)$ captures total discounted continuation profits. To the extent that firms can affect future reimbursement via their second period price, continuation profits are a function of p_2 .

Optimal prices will depend on the effective margin elasticity of demand, since the payment a physician receives is the difference between list price and reimbursement. Define the semi-elasticity of demand with respect to the effective margin as $\eta(m) \equiv \frac{Q'(m)}{Q(m)}$.

In a single-period static model, the monopolist would set prices equal to marginal costs plus a markup, which depends on the effective margin elasticity. In our setting, deviating and raising launch prices *above* the optimal static monopoly price is profitable because it raises future profits. Moreover, the price in the second period is always higher than the static monopoly price for a given level of reimbursement r_2 , provided that continuation profits are increasing in the period two price. Formally, the optimal prices, expressed in terms of the semi-elasticity of demand, $\eta(m)$, are given by:

$$p_1^* = c + \frac{1}{\eta(m_1)} + \underbrace{\delta(p_2^* - c) \frac{Q'(m_2)}{Q'(m_1)} \frac{dm_2}{dp_1}}_{\text{effect of } \uparrow p_1 \text{ on } Q_2 \text{ demand}}, \quad (2)$$

$$p_2^* = c + \frac{1}{\eta(m_2)} + \underbrace{\delta \frac{EV'(p_2)}{Q'(m_2)}}_{\text{effect of } \uparrow p_2 \text{ on continuation profits}}. \quad (3)$$

The pricing decisions are not independent across time because m_2 depends on p_1 ; the optimal launch price depends on the period 2 price and vice versa. The trade-off that the monopolist faces when setting prices in period 2 will vary with the choice of launch price affects the level of reimbursement in period 2. Equation (2) shows that the profitability of raising the period 1 price depends on the profit margin attained in period 2. For example, if generic entry occurs in period 2, competition may lead firms to set prices at marginal

cost. In this scenario, there is no longer an incentive to raise launch price above the static monopoly price in period 1. The *wedges* between lagged-price reimbursement and static monopoly pricing created by the lagged-price reimbursement depend on the marginal effect of raising current prices on future demand through the physician effective margin channel. In our setting, the effect of raising the launch price on the period 2 effective margin depends on the Medicare market share s , the ASP reimbursement multiplier $1 + A$, and the physician's relative weight on profits λ : $\frac{dm_2}{dp_1} = \lambda s(1 + A)$.

Definition 1 *Denote the pricing wedges introduced by the lagged-price reimbursement contract in periods 1 and 2 by Δ_1 and Δ_2 , respectively, where*

$$\Delta_1 \equiv \delta(p_2^* - c) \frac{Q'(m_2)}{Q'(m_1)} \lambda s(1 + A), \quad \text{and} \quad \Delta_2 \equiv \delta \frac{EV'(p_2)}{Q'(m_2)}.$$

We can derive comparative statics for how prices will change when drugs are more exposed to Medicare versus private reimbursement. We make three technical assumptions formalized in the Theoretical Appendix. First, we assume that the physician puts a positive weight on reimbursement and that the patient out-of-pocket share is constant. Second, we assume that conditions hold such that the pharmaceutical's pricing problem is globally convex. Third, we assume that the firm cannot make infinite profits in the future by raising current prices (e.g. continuation value of future profits are not convex in the period two price).

In general, Medicare Part B reimbursement policy's effect on prices is theoretically ambiguous and depends on the demand elasticity with respect to the effective margin, and on the ratio of the private insurance reimbursement rate and the ASP reimbursement multiplier (which governs the magnitude of Medicare reimbursement, relative to private reimbursement). In the appendix, we provide a numerical example that highlights the theoretical ambiguity around the effects of lagged-price reimbursement on prices and pricing dynamics. As a result, more exposure to Part B can either raise or lower total lifetime drug costs.

Next, Proposition 1 shows a set of sufficient conditions under which more exposure to Part B leads to higher launch prices and lower later prices, which is the empirically relevant case given our estimates in the following section (and those of Ridley and Lee (2020) on launch prices).

Proposition 1 *Define $\gamma_t \equiv \frac{Q''(m_t)}{Q'(m_t)}$. Suppose that*

- (a) *private reimbursement is less than Medicare reimbursement in period two:*
- $$\rho \leq (1 + A) \left(c + \frac{1}{\eta(m_1)} + \Delta_1 \right);$$

(b) demand is sufficiently inelastic, such that $\eta(m_2) \leq \left(\frac{1}{\gamma_2} - \Delta_2\right)^{-1}$ and

$$\eta(m_1) \leq \left(\frac{2+\lambda s(1+A)\Delta_1\gamma_2}{\gamma_1} - \Delta_1\right)^{-1};$$

(c) and the physician's effective margin is increasing in Medicare market share, $\frac{dm_2}{ds} \geq 0$;

Then, the equilibrium price in period two is decreasing in Medicare market share and the equilibrium price in period one is increasing in Medicare market share, $\frac{dp_2^*}{ds} \leq 0$ and $\frac{dp_1^*}{ds} \geq 0$.

Proof. See Appendix. ■

Thus, three intuitive conditions will imply a steeper declining price path when more exposed to Medicare's lagged-price reimbursement. Changing Medicare market share has two effects on a physician's reimbursement: a direct effect (the composition of physician reimbursement is more heavily determined by Medicare) and an indirect effect (it affects the equilibrium price). Condition (a) places a condition on how generous Medicare is in its add-on multiplier for lagged-price reimbursement and hence its period 2 reimbursement, so that more Medicare exposure has a positive direct effect on physician reimbursement. Then, condition (b) tells us that physician demand is relatively inelastic.

The direct effect of raising the Medicare reimbursement rate in the second period must outweigh the indirect effect that Medicare market share may have on equilibrium prices. Condition (c) tells us that the change in the equilibrium price is not going to outweigh the compositional changes in the source of the physician reimbursement for the physician's margin. That is, that the direct effect is greater than the indirect effect.

The proof shows that the impact of Medicare market share on period 2's price is governed by the elasticity of demand, by how margin in period 2 is affected by s , and the role of continuation profits beyond period 2. Conditions (b) and (c) suffice to guarantee that p_2 declines in s . Adding condition (a) then guarantees that p_1 is increasing in s .

For expositional clarity, the proposition uses equilibrium objects, rather than primitives. The Appendix describes the set of conditions on primitives such that condition (c) holds, which entails bounds on the relative pricing wedges across periods one and two.

4 Data and Descriptive Statistics

4.1 Data

We construct a sample of prices and Medicare market shares for physician-administered drugs spanning 2006 through 2019. Our unit of analysis is the drug-quarter, where drugs are

uniquely identified by Health Care Procedure Coding System (HCPCS) codes. We combine data from three sources: pricing files, aggregate Medicare claims, and Truven Marketscan spending aggregates.

To measure the price and reimbursement of a drug, we use the Average Sales Price (ASP) of Part B drugs from 2005 through 2019, which are publicly available from the Center for Medicare Services (CMS). ASP data are reported at the HCPCS level. We include only HCPCS introduced later than 2005 and exclude drugs in the ASP files that are reimbursed under alternative methodologies (vaccines and blood/clotting products), limiting to "J Code" HCPCS.

We measure price by inverting the reimbursement rate. The ASP pricing files contain quarterly data on the reimbursement rate, which is a function of the lagged sale price of the drug. We construct our price variable for each drug j in quarter t by taking the reimbursement rate from quarter $t + 2$ and dividing it by 1.06.

To measure exposure to the Medicare Part B program, we construct Medicare market share (MMS) for each HCPCS, following a similar approach to Yurukoglu et al. (2017). We aggregate drug payments both from private insurers and from Medicare, and define MMS for each drug-year as Medicare over Medicare plus private drug payments in that year.

We obtain Medicare’s aggregate drug payments from the CMS Part B National Summary Data File, which contains yearly data on aggregate payments for each HCPCS code in by Part B. We obtain aggregate private drug payments at the HCPCS-year level using Truven MarketScan data for each year. We follow Yurukoglu et al. (2017) and scale these payments up by the ratio all commercial insurance enrollees to the number of Marketscan enrollees in that particular year, assuming that Marketscan provides an approximately nationally representative sample of the commercial insurance market, which allows us to construct a national private drug payments figure.

Our key treatment variable is a drug j ’s Medicare market share at launch, which we term MMS_j . We focus at MMS at launch to measure a persistent characteristic of a drug— its exposure to the pricing incentives created by Medicare Part B. Finally, drugs are launched in different years, so we use τ to describe time in quarters relative to a drug’s launch. The first period that HCPCS is observed is normalized to $\tau = 1$.

4.2 Descriptive Statistics

Prices evolve quite heterogeneously across drugs. We give some examples in Figure 1 Panel A, which displays the price paths (relative to launch price) of the top 10 Medicare Part B expenditure drugs across the 2015-2019 period. We plot prices relative to prices in 2015,

though note that these drugs were introduced at a variety of different times. While many of these drugs show a steady increase across time, there are exceptions, such as Ranibizumab (a drug used for macular degeneration), that show declining prices over time. Various drugs experience a drop in prices after prior increases; these drop-offs are sometimes but not always related to billing-code entry.

Medicare quantity sold, measured as revenue divided by price, varies over time (See Appendix Figure A1). While highly heterogeneous across drugs, on average quantity sold doubles in the first two years post-launch. As a result, prices in later periods contribute more to the volume-weighted lifetime cost of a drug than the launch price, motivating our analysis of the dynamic pricing impact of Part B reimbursement.

Table 1 gives descriptive statistics on our cohort of drugs, and Appendix Figure A2 shows the distribution of MMS at launch. We identify 215 unique HCPCS, and split them into above and below median MMS at launch, which is 0.193. Relative prices 2 years after launch are about 3% higher for above median MMS and 8% higher for below median MMS drugs. However, above Median MMS drugs are about 1.3 years “newer.”

Prices grow at a slow enough rate to leave positive profit margins for the average provider. Constructing the average annual and quarterly growth rate for each drug provides insight into the profits that prescribing providers make. A provider who acquires the drug at a price equal to ASP every quarter will make zero profit margin on a drug whose price grows at 6% over two quarters. (The reimbursement rate will equal acquisition costs in this case.) Note that for prices to grow by 6% over two quarters, the compound quarterly growth rate has to be 2.96%, since $(1.0296)^2 = 1.06$. Here, the mean compound quarterly growth rate is 0.92%.

Figure 1 Panel B shows the price evolution of drugs over time, split by exposure to Part B. We split the sample by whether the drug was above or below median MMS at launch to allow us to compare prices between drugs that are more or less exposed to the Medicare market. This figure normalizes the price at launch ($\tau = 1$) and plots price in later quarters, weighting by total market size. Weighted by market size, prices are 10-20% more expensive 2 years after launch, with greater price growth for drugs more exposed to Part B.

5 Empirical Strategy and Results

5.1 Estimation

Our empirical strategy uses cross-sectional variation in individual drug exposure to the Medicare market to identify the effects of Part B’s lagged ASP reimbursement rule on drug price

growth. We estimate:

$$\ln(p_{jt}) = \beta_{\tau_{jt}} MMS_j \times \tau_{jt} + \tau_{jt} + X_{jt} + \epsilon_{jt} \quad (4)$$

where p_{jt} is the price (ASP) of drug j in year t , τ_{jt} is a set of indicator variables for the quarter relative to when drug j was introduced, MMS_j is the Part B share of drug j 's claims in its first quarter. We include drug and year fixed effects in X_{jt} . Note that MMS_j does not vary over time—it is constant within a drug—and we include drug fixed effects. (MMS is highly correlated within a drug over time, above 0.9.)

The key coefficients of interest are the $\beta_{\tau_{jt}}$, the coefficients on the interactions between time since launch τ_{jt} and MMS_j . The estimates describe how prices in later periods compare to the launch price for HCPCS with relatively high Medicare market share at launch. The identifying assumption is that drugs with different MMS_j would have had the same percentage change in price in later periods in the absence of incentives created by the Medicare reimbursement program. Conditional on drug fixed effects, the regression coefficients can be interpreted as percentage price changes relative to launch. While we cannot identify the effect of Medicare market share on launch prices, this strategy has a number of advantages. For example, we do not need that the price per standardized dosage of one drug is comparable to the price per dosage of another.

We weight our regressions by a drug's average total market size over the time of our sample. This allows us to identify the average causal effect of Medicare market share per dollar spent, rather the average per drug, as there are many small drugs that are relatively unimportant for overall drug spending. (See Solon et al. (2015) on weights).

5.2 Main Results

Panel A of Figure 2 shows that drugs that are more exposed to Medicare Part B have slower price growth. The confidence intervals on each individual interaction coefficient are wide, but we can test the hypothesis that the interactions between MMS and time since launch are all zero ($F(23, 214) = 3.52, p < 0.001$). We thus reject the hypothesis that high Medicare market share drugs have the same price path as low Medicare market share drugs.

To interpret the results, note that the interaction coefficient on $\tau \times MMS_j$ tells us how higher versus Medicare market share drugs will be priced in period τ , relative to their launch price. The interaction coefficient of -0.18 on $\tau = 24 \times MMS_j$ tells us that high Medicare market share drugs will have increased their prices less than low Medicare market share drugs. For a drug sold only to Medicare ($MMS=1$), the estimates predict that after 6 years, its price would be about 18% below a drug with no Medicare market share that launched at

the same price. (They may, however, launch at different prices.)

We summarize our results succinctly in Table 2, which presents results for both the full analysis sample and a balanced panel of drugs. In Column 1, we impose a linear time trend in prices post launch, and interact that with MMS. These specifications indicate that drugs with zero MMS grow at about 0.7% per quarter, while drugs with 100% MMS grow about -0.8 percentage points less per quarter than zero MMS drugs. Results in Column 3 for a balanced panel show a similar pattern, but with a stronger interaction where $MMS = 1$ drugs grow about -1.5 percentage points per quarter less than $MMS = 0$ drugs.

However, a linear specification in time and MMS may not be appropriate. Table 2 also presents a specification in which time period is split into early ($\tau \leq 12$) and late, and drugs are split into above and below median MMS. Holding launch price constant, prices of above median MMS drugs are 11% below those of below median MMS drugs after 3 years in our Analysis Sample, with a smaller estimate for the balanced panel.

Our main analysis examines price and reimbursement for all newly introduced J-codes, regardless of whether the underlying molecule was newly approved. However, the pricing dynamics of older drugs might be different, due to greater generic competition (or the threat thereof), as well as potential anchoring on prices that pre-dated the introduction of the new HCPCS code. Indeed, Appendix Figure A3 shows that competitor entry can happen quickly for new J-codes for existing molecules. To address these concerns, we created a narrow sample of drugs whose molecule FDA approval date was concurrent (within 1 year) with the introduction of the HCPCS code.⁸ The resulting estimates displayed in Panel B of Figure 2 show that the MMS interaction effects are larger in magnitude and more precisely estimated in this sample, with coefficients approximately -0.13 after 12 quarters and -0.29 after 24 quarters, compared to about -.09 and -0.18 in our main results. This suggests our main specification is conservative.⁹

5.3 Robustness

Appendix Figure A5 shows that our results are robust to using a variety of alternative two-way fixed effects estimators that remove these concerns. Point estimates in each case are quite similar. (To test robustness to alternative estimators, we need to discretize our treatment. We do this by splitting our sample into above versus below median MMS, as in Table 2.)

⁸This required merging the HCPCS to NDC using string matching on drug names. The narrow sample is smaller— 88 unique HCPCS, rather than 215 in our main analysis sample. Appendix Figure A4 shows that this sample has a longer time until competitor entry in the billing code.

⁹A linear specification in time gives a coefficient on $\tau \times MMS$ of -0.013, about twice that in Table 2 column 1.

We also consider a series of additional robustness checks in Appendix Figure A6. Each panel presents an analogue of Figure 2 Panel A run on a different sample. In Panel A, we show that excluding outliers does not meaningfully affect our results. In Panel B, we weight all drugs equally, rather than by drug market size. The results are noisier, though the point estimates are larger in magnitude. To address any concerns that our results are driven by an unbalanced panel, we construct a sample with a balanced panel. We first shorten our estimation window to the first 4 years since launch in order to maximize sample size, and show the regression results on an unbalanced panel in Panel C. Panel D then shows the balanced panel results. The results are quite similar, and in fact more precisely estimated than our main results.

In Appendix Figure A7, we consider a set of additional robustness checks related to sample composition. Panel A reproduces our main Figure 2 on a common axis for reference. The negative trend becomes, if anything, stronger in three robustness checks: excluding the initial (and largest) cohort of observations in Panel B, excluding small cohorts of two or fewer drugs in Panel C, and excluding drugs that ever have a period of missing price data in Panel D. We also examine whether the effect of MMS is different in cohorts of drugs introduced sooner versus later after Part B’s lagged-price reimbursement system was introduced. Appendix Table A1 shows no clear evidence that the effect is different for these cohorts.

Finally, to address concerns that MMS might be endogenous to firm pricing strategy, we create another independent measure of exposure to Medicare’s pricing incentives. We examine individuals with commercial insurance not on Medicare, and compare drugs with higher market share among older versus younger commercially insured individuals. The correlation at launch between MMS and this alternative measure is 0.46. Appendix Tables A2 and A3 give details and show that we find similar and perhaps more negative estimated impacts of this alternative measure of exposure on price growth.

5.4 Medicare Market Share and Launch Price

To place in context our estimates of the dynamic effects of lagged-price reimbursement, we also provide estimates of the impact of Medicare Part B on initial launch price. We view these estimates with skepticism. Our main results include drug fixed effects and simply require that counterfactual percentage changes in prices be the same across groups. However, to identify whether drugs with higher Part B exposure have higher launch prices, we must remove drug fixed effects from our regression. The identification assumption required is now much stronger: in the absence of Part B’s reimbursement formula, the types of drugs

with greater exposure to Medicare Part B would have had initial prices that were the same on average as drugs with less exposure to Part B. Moreover, in the absence of a clearly comparable unit of measure for drug pricing, we anticipate greater variation in measured HCPCS prices.

Nonetheless, Table A4 shows the results of regressions that parallel those in our Table 2, but now drops drug fixed effects and displays the effect of MMS_j on launch prices. We estimate that drugs with above median MMS have launch prices that are 64 log points (90%) higher, but this is imprecisely estimated and we cannot reject declines of 26 log points or increases of 154 log points. Despite the imprecision, these results plus those of Ridley and Lee (2020), suggest that the effects of Part B on initial price are larger than the declines in later periods.¹⁰

6 Implications

What is the overall impact of high (above-median) exposure to Medicare on the lifecycle price of drugs? In theory, exposure to lagged-price reimbursement could raise or lower the life-cycle price.

We compare our estimates to the estimates we would get if we ignored the dynamic price effect and simply extrapolated the estimated Part B effect on launch price to all future periods. We focus on the first 6 years (24 quarters), and assume no difference after that time, as this is the window for which we are able to estimate results. The lifecycle price of a drug is $\frac{\sum_{\tau=1}^{24} p_{\tau} Q_{\tau}}{\sum_{\tau=1}^{24} Q_{\tau}}$, ignoring discounting over this short horizon. Each period’s price is weighted by the quantity sold Q_{τ} in that period using the estimates from Figure A1.

Our estimate of the effect of being above median MMS in years 3-6 comes from Table 2 Column 2. The estimate of the effect of being above median MMS on launch is taken from Table A4 Column 2. We transform these log point changes into percentage changes. Naively extrapolating the launch price effect implies that being above median MMS raises lifecycle price by 89%. However, the lifecycle price is actually only 79% higher accounting for the decline in years 3-6. Ignoring the dynamic price changes would lead to an overestimate of the lifecycle price.

The estimated net effect is that more exposure to Part B leads to higher lifecycle prices. This result is robust to a range of possible launch price effects— it holds even if the actual

¹⁰Ridley and Lee (2020) estimates that the average effect of being exposed to Part B’s lagged-price reimbursement payment system, compared to Medicare’s previous reimbursement system, was a 0.61 log point price increase at launch. That estimate is not directly comparable to ours, as our estimate comes from variation in exposure to Medicare versus private payment.

increase in launch price was only about one-tenth our observed estimate.

7 Conclusion

Understanding the dynamic pricing incentives in lagged-price reimbursement contracts is important. Our model and empirical analysis show that these contracts can shape the market prices that they in turn rely on. We find that lagged cost-based reimbursement in Medicare Part B creates incentives to launch at high prices and then lower them over time.

Future theoretical work should explore the impact of price dispersion and negotiation in the model. Future empirical work should examine how providers respond to changes in margin and how that affects patient health. Moreover, because Medicare Part B reimbursement design affects prices and thus drug profitability, it may have impacted innovation.

Understanding how payment policy affects the pricing of pharmaceuticals is necessary to evaluate policy reforms, such as reforms included in the 2022 Inflation Reduction Act. The impact depends on both policy parameters and the elasticity of demand. Our model can be used by policy-makers with context-specific estimates to predict how the design of contracting in Medicare Part B will impact overall costs. It could also enrich models of external reference pricing (in which countries set prices based on lagged-prices in other countries, see e.g. Maini and Pammolli (2023)) and can be used for other non-pharmaceutical industries.

References

- Bajari, Patrick and Steven Tadelis**, “Incentives versus Transaction Costs: A Theory of Procurement Contracts,” *The RAND Journal of Economics*, 2001, *32* (3), 387–407.
- Bosio, Erica, Simeon Djankov, Edward Glaeser, and Andrei Shleifer**, “Public Procurement in Law and Practice,” *American Economic Review*, April 2022, *112* (4), 1091–1117.
- Crocker, Keith J. and Kenneth J. Reynolds**, “The Efficiency of Incomplete Contracts: An Empirical Analysis of Air Force Engine Procurement,” *The RAND Journal of Economics*, 1993, *24* (1), 126–146.
- Cutler, David M.**, “Medicare Enters the Pharmaceutical Purchasing Business,” *JAMA Health Forum*, September 2022, *3* (9), e223630.
- Decarolis, Francesco**, “Medicare part d: Are insurers gaming the low income subsidy design?,” *American Economic Review*, 2015, *105* (4), 1547–1580.
- Desai, Sunita and J Michael McWilliams**, “Consequences of the 340B drug pricing program,” *New England Journal of Medicine*, 2018, *378* (6), 539–548.
- Dubois, Pierre, Ashvin Gandhi, and Shoshana Vasserman**, “Bargaining and International Reference Pricing in the Pharmaceutical Industry,” *National Bureau of Economic Research Working Paper 30053*, May 2022.
- Duggan, Mark and Fiona Scott Morton**, “The Effect of Medicare Part D on Pharmaceutical Prices and Utilization,” *American Economic Review*, March 2010, *100* (1), 590–607.
- Ericson, Keith M.**, “Consumer inertia and firm pricing in the Medicare Part D prescription drug insurance exchange,” *American Economic Journal: Economic Policy*, 2014, *6* (1), 38–64.
- Farrell, Joseph and Carl Shapiro**, “Dynamic Competition with Switching Costs,” *The RAND Journal of Economics*, 1988, *19* (1), 123–137.
- Gaynor, Martin, Nirav Mehta, and Seth Richards-Shubik**, “Optimal Contracting with Altruistic Agents: Medicare Payments for Dialysis Drugs,” *American Economic Review*, June 2023, *113* (6), 1530–1571.

- Ginsburg, Paul and Steven Lieberman**, “Medicare payment for physician-administered (Part B) drugs,” *USC-Brookings Schaeffer Initiative for Health Policy Working Paper*, February 2021.
- Howard, David H., Peter B. Bach, Ernst R. Berndt, and Rena M. Conti**, “Pricing in the Market for Anticancer Drugs,” *Journal of Economic Perspectives*, February 2015, 29 (1), 139–162.
- Ippolito, Benedic N and Joseph F Levy**, “The Influence of Medicare Part D on the List Pricing of Brand Drugs,” *Health Services Research*, 2023.
- Jacobson, Mireille, Craig C Earle, Mary Price, and Joseph P Newhouse**, “How Medicare’s payment cuts for cancer chemotherapy drugs changed patterns of treatment,” *Health Affairs*, 2010, 29 (7), 1391–1399.
- Ji, Yunan and Parker Rogers**, “The Dynamic Effects of Health Care Price Reform,” *Working Paper*, 2023.
- Kang, Karam and Robert A Miller**, “Winning by Default: Why is There So Little Competition in Government Procurement?,” *The Review of Economic Studies*, May 2022, 89 (3), 1495–1556.
- Kosmopoulou, Georgia and Xueqi Zhou**, “Price Adjustment Policies in Procurement Contracting: An Analysis of Bidding Behavior,” *The Journal of Industrial Economics*, 2014, 62 (1), 77–112.
- Krasnokutskaya, Elena and Katja Seim**, “Bid Preference Programs and Participation in Highway Procurement Auctions,” *American Economic Review*, October 2011, 101 (6), 2653–2686.
- Lakdawalla, Darius N.**, “Economics of the Pharmaceutical Industry,” *Journal of Economic Literature*, June 2018, 56 (2), 397–449.
- Maini, Luca and Fabio Pammolli**, “Reference pricing as a deterrent to entry: evidence from the European pharmaceutical market,” *American Economic Journal: Microeconomics*, 2023, 15 (2), 345–383.
- Medicare Payment Advisory Commission**, “MedPAC July 2022 Data Book, Section 10: Prescription drugs,” 2022.
- Morton, Fiona Scott and Lysle T Boller**, “Enabling competition in pharmaceutical markets,” *Hutchins Center Working Paper 30*, 2017.

Polite, Blase, Rena M Conti, and Jeffery C Ward, “Reform of the buy-and-bill system for outpatient chemotherapy care is inevitable: perspectives from an economist, a realpolitik, and an oncologist,” *American Society of Clinical Oncology Educational Book*, 2015, *35* (1), e75–e80.

Ridley, David B. and Chung-Ying Lee, “Does Medicare Reimbursement Drive Up Drug Launch Prices?,” *The Review of Economics and Statistics*, December 2020, *102* (5), 980–993.

– **and Su Zhang**, “Regulation of Price Increases,” *International Journal of Industrial Organization*, 2017, *50*, 186–213.

Solon, Gary, Steven J. Haider, and Jeffrey M. Wooldridge, “What Are We Weighting For?,” *Journal of Human Resources*, March 2015, *50* (2), 301–316.

Yurukoglu, Ali, Eli Liebman, and David B. Ridley, “The Role of Government Reimbursement in Drug Shortages,” *American Economic Journal: Economic Policy*, May 2017, *9* (2), 348–382.

Table 1: Descriptive Statistics of Drugs

	Full Sample		Above Median MMS	Below Median MMS
	<i>Mean</i>	<i>Std Dev</i>	<i>Mean</i>	<i>Mean</i>
Medicare Market Share (MMS) at $\tau = 1$	0.270	0.261	0.480	0.062
Relative ASP at $\tau = 8$	1.058	0.335	1.032	1.083
Average Year of Introduction	2010.7	3.8	2011.4	2010.1
Compound Annual Growth Rate over first 6 years	0.0409	0.1000	0.0196	0.0572
Compound Quarterly Growth Rate over first 6 years	0.0092	0.0239	0.0041	0.0131
N (Unique HCPCS)	215		107	108

Notes: Source: Authors' calculations from CMS Data 2006-2019. Median Medicare Market Share at Launch = 0.193


Table 2: Summarizing the Effect of MMS on Price Evolution

	(1)	(2)	(3)	(4)
	Analysis Sample		Balanced Panel	
τ	0.007		0.008***	
	(0.005)		(0.002)	
$\tau \times \text{MMS}$	-0.008*		-0.015***	
	(0.005)		(0.005)	
$\tau > 12$		0.079**		0.033**
		(0.035)		(0.014)
$\tau > 12 \times \text{Above Median MMS} = 1$		-0.111**		-0.030***
		(0.051)		(0.005)
Drug Fixed Effects	Yes	Yes	Yes	Yes
Year Fixed Effects	Yes	Yes	Yes	Yes
R^2	0.070	0.087	0.383	0.364
N	4502	4502	588	588


Notes: *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$ Dependent variable: $\ln p_{jt}$. Robust standard errors clustered at the HCPCS level. Balanced panel only uses observations with $\tau \leq 16$ and requires that all drugs have at least $\tau = 16$.

Figure 1: Price Evolution of Medicare Part B Drugs

(A) Price Evolution of Top 10 Medicare Part B Drugs




(B) Price Evolution of Drugs by Exposure to Medicare Part B




Notes: Panel A: Selects the top 10 Part B drugs by Medicare revenue 2015-2019. Panel B: Price relative to launch by exposure to Medicare. Relative price is ASP in quarter τ divided by ASP in quarter $\tau = 1$. Plots the results of a regression of relative quantity against quarter τ fixed effects and year fixed effects weighted by total drug market size.

Figure 2: Exposure to Medicare Part B and Drug Prices

(A) Estimates of MMS Interaction Effect: Full Sample



(B) Estimates of MMS Interaction Effect: Newly Approved Molecules



Notes: Panel A: Plots point estimates and 95% confidence intervals for coefficients estimated by the regression given in Equation 4 on the Analysis Sample weighted by total drug market size. Panel B: Same as panel A, but estimated on sample of newly approved molecules. Robust standard errors clustered at the HCPCS level.

Online Appendix For: “Lagged-Price Reimbursement Contracts: The Impact of Medicare Part B on Pharmaceutical Price Growth”

Angie Acquatella, Keith Marzilli Ericson, and Amanda Starc

I Theoretical Appendix

Assumptions

Formally, the assumptions we make about the demand system are given by:

1. the physician puts a positive weight on reimbursement, $\lambda > 0$, and that the patient out-of-pocket share is constant, $\frac{oop(r_t)}{r_t} = k \forall r_t$ for some $k \in \mathbb{R}^+$.
2. that $Q''(m_t) \geq 0$ and bounded above such that the second order conditions for both the static and dynamic monopoly pricing problem hold at every period t :

$$(p_t - c)Q''(m_t) - 2Q'(m_t) \leq 0, \quad \forall t \quad (5)$$

$$(p_1 - c) \cdot Q''(m_1) - 2Q'(m_1) + \delta \lambda^2 s^2 (1 + A)^2 Q''(m_2) \leq 0, \quad (6)$$

3. and that the effect of p_2 on continuation profits is non-convex, such that $\frac{d^2 EV(p_2)}{dp_2^2} \leq 0$.

Definitions

Reimbursement, r_t , expected by the physician is a linear combination of the Medicare rate and the private insurance rate, weighted by the Medicare market share of sales.¹¹ When $t > 1$, the Medicare reimbursement rate r_t^M is a function of the previous period price based on the ASP reimbursement formula, and is given by $r_t^M = (1 + A)p_{t-1}$ with $A > 0$.

Private reimbursement, ρ_t , may follow Medicare to some extent, but we assume it is at least partially independent (e.g. paying based on value, negotiated prices, or considering the value of alternative treatment). Private reimbursement can be decomposed as $r_t^P = (1 - \alpha)\rho_t + \alpha r_t^M$ where $\alpha \in [0, 1)$ indicates the extent to which private insurers follow Medicare, and ρ_t is the private sector’s independent component of price setting, which is determined outside the model.

¹¹We assume that physicians do not tailor their drug choice to the insurance status of the patient, though this is not consequential.

Definition 2 Define the effective Medicare market share s to be $s = \tilde{s} + (1 - \tilde{s})\alpha$, where \tilde{s} is the Medicare market share, $1 - \tilde{s}$ be private market share, and α the extent to which private insurers follow Medicare.

Proofs

Lemma 1 The marginal effect of Medicare market share s on the optimal prices, p_1^* and p_2^* , can be characterized by:

$$\frac{dp_1^*}{ds} = \frac{\frac{\Delta_1}{s} + \Delta_1 \gamma_2 \frac{dm_2}{ds} + \frac{\Delta_1}{\frac{1}{\eta(m_2)} + \Delta_2} \frac{dp_2^*}{ds}}{2 - \left(\frac{1}{\eta(m_1)} + \Delta_1 \right) \gamma_1}, \quad \text{and} \quad \frac{dp_2^*}{ds} = \frac{\left(1 - \left(\frac{1}{\eta(m_2)} + \Delta_2 \right) \gamma_2 \right) \frac{dm_2}{ds}}{\left(1 - \delta \frac{EV''(p_2)}{Q'(m_2)} \right)}.$$

where $\gamma_t \equiv \frac{Q''(m_t)}{Q'(m_t)}$ is curvature of the demand function, and Δ_1 and Δ_2 the pricing wedges introduced by the lagged-price reimbursement contract defined in Definition (1).

Proof. We begin by totally differentiating the optimal prices p_1^* and p_2^* with respect to s .

$$\begin{aligned} \frac{dp_1^*}{ds} &= -\frac{d}{dm_1} \left[\frac{1}{\eta(m_1)} \right] \frac{dp_1^*}{ds} + \delta \lambda (1 + A) (p_2^* - c) \left(s \frac{Q''(m_2)}{Q'(m_1)} \frac{dm_2}{ds} + s \frac{Q'(m_2)}{Q'(m_1)} \frac{Q''(m_1)}{Q'(m_1)} \frac{dp_1^*}{ds} + \frac{Q'(m_2)}{Q'(m_1)} \right) \\ &\quad + \delta \lambda s (1 + A) \frac{Q'(m_2)}{Q'(m_1)} \frac{dp_2^*}{ds} \\ \frac{dp_2^*}{ds} &= \frac{d}{dm_2} \left[\frac{1}{\eta(m_2)} \right] \frac{dm_2}{ds} + \delta \frac{EV''(p_2)}{Q'(m_2)} \frac{dp_2^*}{ds} - \delta EV'(p_2) \frac{Q''(m_2)}{Q'(m_2)^2} \frac{dm_2}{ds} \end{aligned}$$

Substituting in for $\gamma_t \equiv \frac{Q''(m_t)}{Q'(m_t)}$, $\Delta_1 \equiv \delta (p_2^* - c) \sigma_{21} \lambda s (1 + A)$, $\Delta_2 \equiv \delta \frac{EV'(p_2)}{Q'(m_2)}$, and $p_2^* - c = \frac{1}{\eta(m_2)} + \Delta_2$, we obtain:

$$\begin{aligned} \frac{dp_1^*}{ds} &= \left(-1 + \frac{1}{\eta(m_1)} \gamma_1 \right) \frac{dp_1^*}{ds} + \Delta_1 \gamma_2 \frac{dm_2}{ds} + \Delta_1 \gamma_1 \frac{dp_1^*}{ds} + \frac{\Delta_1}{s} + \frac{\Delta_1}{\frac{1}{\eta(m_2)} + \Delta_2} \frac{dp_2^*}{ds} \\ \frac{dp_2^*}{ds} &= \left(1 - \frac{1}{\eta(m_2)} \gamma_2 \right) \frac{dm_2}{ds} + \delta \frac{EV''(p_2)}{Q'(m_2)} \frac{dp_2^*}{ds} - \Delta_2 \gamma_2 \frac{dm_2}{ds} \end{aligned}$$

Rearranging to solve for $\frac{dp_1^*}{ds}$ and $\frac{dp_2^*}{ds}$, and expressing the second derivative terms as functions of θ_t results in:

$$\frac{dp_1^*}{ds} = \frac{\frac{\Delta_1}{s} + \Delta_1 \gamma_2 \frac{dm_2}{ds} + \frac{\Delta_1}{\frac{1}{\eta(m_2)} + \Delta_2} \frac{dp_2^*}{ds}}{2 - \left(\frac{1}{\eta(m_1)} + \Delta_1 \right) \gamma_1}, \quad \text{and} \quad \frac{dp_2^*}{ds} = \frac{\left(1 - \left(\frac{1}{\eta(m_2)} + \Delta_2 \right) \gamma_2 \right) \frac{dm_2}{ds}}{\left(1 - \delta \frac{EV''(p_2)}{Q'(m_2)} \right)}.$$

■

Proposition 1 Define $\gamma_t \equiv \frac{Q''(m_t)}{Q'(m_t)}$. Suppose that

(a) private reimbursement is less than Medicare reimbursement in period two:

$$\rho \leq (1 + A) \left(c + \frac{1}{\eta(m_1)} + \Delta_1 \right);$$

(b) demand is sufficiently inelastic, such that $\eta(m_2) \leq \left(\frac{1}{\gamma_2} - \Delta_2 \right)^{-1}$ and

$$\eta(m_1) \leq \left(\frac{2 + \lambda s(1 + A)\Delta_1\gamma_2}{\gamma_1} - \Delta_1 \right)^{-1};$$

(c) and the physician's effective margin is increasing in Medicare market share, $\frac{dm_2}{ds} \geq 0$;

Then, the equilibrium price in period two is decreasing in Medicare market share and the equilibrium price in period one is increasing in Medicare market share, $\frac{dp_2^*}{ds} \leq 0$ and $\frac{dp_1^*}{ds} \geq 0$.

Proof. Conditions (b) and (c) jointly imply that $\frac{dp_2}{ds} \leq 0$.

$$\frac{dp_2^*}{ds} = \underbrace{\frac{\overbrace{dm_2/ds}^{\geq 0 \text{ by (c)}}}{1 - \delta EV''(p_2)/Q'(m_2)}}_{\geq 0 \text{ by construction}} \cdot \underbrace{\left(1 - \left(\frac{1}{\eta(m_2)} + \Delta_2 \right) \gamma_2 \right)}_{\leq 0 \text{ by (b)}} \leq 0$$

At the equilibrium prices, the effect of s on the physician's effective margin is given by the following expression:

$$\frac{dm_2}{ds} = \underbrace{\lambda s(1 + A) \frac{dp_1^*}{ds} - \frac{dp_2^*}{ds}}_{\text{equilibrium effect of } s \text{ on prices}} + \underbrace{\lambda ((1 + A)p_1^* - \rho)}_{\text{direct effect of } s \text{ on effective margin}},$$

where the last term is positive when (a) holds, and the second to last term is positive when (b) and (c) hold. From Lemma 1 and the expression for $\frac{dm_2}{ds}$, we can establish that $\frac{dp_1^*}{ds}$ is characterized by:

$$\left(-2 + \left(\frac{1}{\eta(m_1)} + \Delta_1 \right) \gamma_1 \right) \frac{dp_1^*}{ds} = \frac{\Delta_1}{s} + \frac{\Delta_1}{\frac{1}{\eta(m_2)} + \Delta_2} \frac{dp_2^*}{ds} + \underbrace{\Delta_1 \gamma_2 \left(\lambda s(1 + A) \frac{dp_1^*}{ds} - \frac{dp_2^*}{ds} + \lambda ((1 + A)p_1^* - \rho) \right)}_{\frac{dm_2}{ds}}.$$

Rearranging to isolate $\frac{dp_1}{ds}$ gives us that:

$$\frac{dp_1^*}{ds} = \frac{\overbrace{\frac{\Delta_1}{s}}^{\geq 0} + \overbrace{\Delta_1 \left(\gamma_2 - \frac{1}{\frac{1}{\eta(m_2)} + \Delta_2} \right)}^{\geq 0 \text{ by (b)}} \underbrace{\left(-\frac{dp_2^*}{ds} \right)}_{\geq 0 \text{ by (b) and (c)}} + \overbrace{\Delta_1 \gamma_2 \lambda ((1+A)p_1^* - \rho)}^{\geq 0 \text{ by (a)}}}{\underbrace{\left(-2 + \left(\frac{1}{\eta(m_1)} + \Delta_1 \right) \gamma_1 - \Delta_1 \gamma_2 \lambda s(1+A) \right)}_{\geq 0 \text{ by (b)}}}$$

Thus, conditions (a), (b), and (c) jointly imply that $\frac{dp_1^*}{ds} \geq 0$, and conditions (b) and (c) jointly imply that $\frac{dp_2^*}{ds} \leq 0$. ■

Lemma 2 *The equilibrium effect of Medicare market share s on the physician's relative margin in period 2, given optimal prices, is given by*

$$\frac{dm_2}{ds} = \frac{\left(2 - \left(\frac{1}{\eta(m_1)} + \Delta_1 \right) \gamma_1 \right) \delta \sigma_{21} \lambda ((1+A) \left(c + \frac{1}{\eta(m_1)} + \Delta_1 \right) - \rho) + \frac{1}{s} \frac{\Delta_1^2}{\left(\frac{1}{\eta(m_2)} + \Delta_2 \right)}}{\left(\delta \sigma_{21} \left(2 - \left(\frac{1}{\eta(m_1)} + \Delta_1 \right) \gamma_1 \right) - \left(\frac{\Delta_1^2}{\left(\frac{1}{\eta(m_2)} + \Delta_2 \right)} \gamma_2 - \left(1 - \left(\frac{\Delta_1}{\frac{1}{\eta(m_2)} + \Delta_2} \right)^2 \right) \frac{\left(1 - \left(\frac{1}{\eta(m_2)} + \Delta_2 \right) \gamma_2 \right)}{\left(1 - \delta \frac{EV''(p_2)}{Q'(m_2)} \right)} \right)} \quad (7)$$

Proof. We proceed by solving for $\frac{dm_2}{ds}$ explicitly. At the equilibrium prices,

$$\frac{dm_2}{ds} = \underbrace{\lambda s(1+A) \frac{dp_1^*}{ds} - \frac{dp_2^*}{ds}}_{\text{equilibrium effect of } s \text{ on prices}} + \underbrace{\lambda ((1+A)p_1^* - \rho)}_{\text{direct effect of } s \text{ on effective margin}}.$$

Notice that the partial effect of s simultaneously affects both prices, $\frac{dp_1^*}{ds}$ and $\frac{dp_2^*}{ds}$, and these, in turn, depend on $\frac{dm_2}{ds}$. Thus, we need to solve a system of equations to obtain the explicit effect of s on m_2 . Substituting in for p_1^* from equation (2), and $\frac{dp_1^*}{ds}, \frac{dp_2^*}{ds}$ from Lemma 1, we the following equilibrium relationship that allows us to solve for $\frac{dm_2}{ds}$ explicitly. Simplifying

yields the following expression:

$$\begin{aligned}
\frac{dm_2}{ds} = & \lambda s(1+A) \frac{\frac{\Delta_1}{s} + \Delta_1 \gamma_2 \frac{dm_2}{ds} + \frac{\Delta_1}{\frac{1}{\eta(m_2)} + \Delta_2} \frac{\left(1 - \left(\frac{1}{\eta(m_2)} + \Delta_2\right) \gamma_2\right)}{\left(1 - \delta \frac{EV''(p_2)}{Q'(m_2)}\right)} \frac{dm_2}{ds}}{2 - \left(\frac{1}{\eta(m_1)} + \Delta_1\right) \gamma_1} & (\text{equilibrium effect of } s \text{ on } p_1^*) \\
& - \frac{\left(1 - \left(\frac{1}{\eta(m_2)} + \Delta_2\right) \gamma_2\right)}{\left(1 - \delta \frac{EV''(p_2)}{Q'(m_2)}\right)} \frac{dm_2}{ds} & (\text{equilibrium effect of } s \text{ on } p_2^*) \\
& + \lambda((1+A)p_1^* - \rho). & (\text{direct effect of } s \text{ on provider's effective margin } m_2)
\end{aligned}$$

Rearranging and solving for $\frac{dm_2}{ds}$ explicitly results in the following expression:

$$\frac{dm_2}{ds} = \frac{\left(2 - \left(\frac{1}{\eta(m_1)} + \Delta_1\right) \gamma_1\right) \delta \sigma_{21} \lambda ((1+A) \left(c + \frac{1}{\eta(m_1)} + \Delta_1\right) - \rho) + \frac{1}{s} \frac{\Delta_1^2}{\left(\frac{1}{\eta(m_2)} + \Delta_2\right)}}{\left(\delta \sigma_{21} \left(2 - \left(\frac{1}{\eta(m_1)} + \Delta_1\right) \gamma_1\right) - \left(\frac{\Delta_1^2}{\left(\frac{1}{\eta(m_2)} + \Delta_2\right)} \gamma_2 - \left(1 - \left(\frac{\Delta_1}{\left(\frac{1}{\eta(m_2)} + \Delta_2\right)}\right)^2\right) \frac{\left(1 - \left(\frac{1}{\eta(m_2)} + \Delta_2\right) \gamma_2\right)}{\left(1 - \delta \frac{EV''(p_2)}{Q'(m_2)}\right)}\right)\right)}$$

■

Corollary 1 *Suppose that:*

- (a) *private reimbursement is less than Medicare reimbursement in period two:*
 $\rho \leq (1+A) \left(c + \frac{1}{\eta(m_1)} + \Delta_1\right);$
- (b) *that demand is sufficiently inelastic, such that $\eta(m_2) \leq \left(\frac{1}{\gamma_2} - \Delta_2\right)^{-1}$ and $\eta(m_1) \leq \left(\frac{2+\lambda s(1+A)\Delta_1\gamma_2}{\gamma_1} - \Delta_1\right)^{-1}$ (equivalent to $\frac{1}{\eta(m_2)} + \Delta_2 \geq \frac{1}{\gamma_2}$);*
- (d) *that the square of the pharmaceutical firm's profit margin in period two is bounded below by the square of the pricing wedge in period one;*

$$\left(\frac{1}{\eta(m_2)} + \Delta_2\right)^2 \geq \Delta_1^2$$

- (e) *and that the pharmaceutical firm's profit margin in period two is bounded below by the square of the pricing wedge in period one times the curvature in period two;*

$$\left(\frac{1}{\eta(m_2)} + \Delta_2\right) \geq \Delta_1^2 \gamma_2$$

(f) that marginal costs are not too large such that $c \leq \frac{1}{\delta\sigma_{21}s^2\lambda^2\gamma_2^2(1+A)^2}$.

Then, the physician's effective margin is increasing in Medicare market share, $\frac{dm_2}{ds}$ when

Proof.

$$\frac{dm_2}{ds} = \frac{\left(2 - \left(\frac{1}{\eta(m_1)} + \Delta_1\right)\gamma_1\right)\delta\sigma_{21}\lambda((1+A)\left(c + \frac{1}{\eta(m_1)} + \Delta_1\right) - \rho) + \frac{1}{s}\frac{\Delta_1^2}{\left(\frac{1}{\eta(m_2)} + \Delta_2\right)}}{\left(\delta\sigma_{21}\left(2 - \left(\frac{1}{\eta(m_1)} + \Delta_1\right)\gamma_1\right) - \left(\frac{\Delta_1^2}{\left(\frac{1}{\eta(m_2)} + \Delta_2\right)}\gamma_2 - \left(1 - \left(\frac{\Delta_1}{\frac{1}{\eta(m_2)} + \Delta_2}\right)^2\right)\frac{\left(1 - \left(\frac{1}{\eta(m_2)} + \Delta_2\right)\gamma_2\right)}{\left(1 - \delta\frac{EV''(p_2)}{Q'(m_2)}\right)}\right)\right)}$$

The denominator of $\frac{dm_2}{ds}$ is always positive when conditions (b), (d), and (e) hold because it can be rearranged to an inequality where the left-hand-side is positive and the right-hand-side is negative.

$$\begin{aligned} & \underbrace{\left(\left(\frac{1}{\eta(m_2)} + \Delta_2\right)^2 - \Delta_1^2\right)}_{\geq 0 \text{ by (d)}} \underbrace{\frac{\overbrace{\left(\left(\frac{1}{\eta(m_2)} + \Delta_2\right)\gamma_2 - 1\right)}^{\geq 0 \text{ by (b)}}}{\delta\sigma_{21}\left(1 - \delta\frac{EV''(p_2)}{Q'(m_2)}\right)\left(-2 + \left(\frac{1}{\eta(m_1)} + \Delta_1\right)\gamma_1\right)}}_{\substack{\geq 0 \text{ by construction} \\ \geq \Delta_1\gamma_2\lambda s(1+A) \geq 0 \text{ by (b)}}} \underbrace{\geq \Delta_1^2\gamma_2\left(\frac{1}{\eta(m_2)} + \Delta_2\right) - \left(\frac{1}{\eta(m_2)} + \Delta_2\right)^2}_{\leq 0 \text{ by (e)}} \\ & \Rightarrow \left(\delta\sigma_{21}\left(2 - \left(\frac{1}{\eta(m_1)} + \Delta_1\right)\gamma_1\right) - \left(\frac{\Delta_1^2}{\left(\frac{1}{\eta(m_2)} + \Delta_2\right)}\gamma_2 - \left(1 - \left(\frac{\Delta_1}{\frac{1}{\eta(m_2)} + \Delta_2}\right)^2\right)\frac{\left(1 - \left(\frac{1}{\eta(m_2)} + \Delta_2\right)\gamma_2\right)}{\left(1 - \delta\frac{EV''(p_2)}{Q'(m_2)}\right)}\right)\right) \geq 0 \end{aligned}$$

The numerator of $\frac{dm_2}{ds}$ is also positive when (a), (b), and (f) hold because it can be rearranged to an inequality that reduces to the assumed positive condition in (f).

$$\begin{aligned} & \frac{\Delta_1^2\gamma_2}{\left(\frac{1}{\eta(m_2)} + \Delta_2\right)} + \left(-2 + \left(\frac{1}{\eta(m_1)} + \Delta_1\right)\gamma_1\right)\delta\sigma_{21}\gamma_2s\lambda(1+A)\left(-c - \left(\frac{1}{\eta(m_1)} + \Delta_1 - \frac{\rho}{(1+A)}\right)\right) \\ & \geq \underbrace{1}_{\text{by (e)}} + \underbrace{\Delta_1\gamma_2\lambda s(1+A)}_{\text{by (b)}}\delta\sigma_{21}\gamma_2s\lambda(1+A)\left(-c + \underbrace{0}_{\text{by (a)}}\right) \\ & = \underbrace{1 - \delta\sigma_{21}s^2\lambda^2\gamma_2^2(1+A)^2c}_{\geq 0 \text{ by (f)}} \geq 0 \end{aligned}$$

■


II Illustrative Example with Linear Demand

To illustrate the ambiguity of lagged-price reimbursement on prices and total lifecycle drug costs, consider a simple numerical example with linear demand where the quantity demanded is exactly equal to the effective margin, $Q(m_t) = m_t = \lambda r_t - p_t$, and continuation value profits after the second period are zero (e.g. generic competition).


Figure A0 Panel A shows a case in which initial price increases in Medicare market share, while second period price decreases, and average lifecycle price is nearly (though not exactly) constant. However, with a higher ASP markup, Figure A0 Panel B shows a case where launch price increases in Medicare market share, but second period price is non-monotonic in market share. Finally, Figure A0 Panel C shows a case with higher discounting and low Medicare initial reimbursement. Here, both prices decrease in Medicare market share, and p_2 is higher than p_1 at many points.

Figure A0: Illustrative Theoretical Examples


(A) Case 1: $A = 0.09$



(B) Case 2: $A = 0.35$



(C) Case 3: $A = 0.35, \delta = 0.5$, and low initial reimbursement



Notes: Assumes linear demand, no continuation value beyond period 2 and marginal cost = 0.5. Case 1: $r_1^M = \rho = 5$, $A = 0.09$, $\delta = 1$. Case 2: $r_1^M = \rho = 5$, $A = 0.35$, $\delta = 1$. Case 3: $r_1^M = 1$, $\rho = 5$, $A = 0.35$, $\delta = 0.5$

Table A1: Effect of MMS on Price Growth: Early Versus Late Cohorts

	(1)	(2)	(3)	(4)
	Early Cohort (2005-2011)		Late Cohort (2012-2019)	
τ	0.004		0.008***	
	(0.007)		(0.002)	
$\tau \times \text{MMS}$	-0.007		-0.011***	
	(0.008)		(0.004)	
$\tau > 12$		0.112		0.057**
		(0.071)		(0.027)
$\tau > 12 \times \text{AboveMedianMMS} = 1$		-0.152*		-0.062**
		(0.087)		(0.031)
Drug Fixed Effects	Yes	Yes	Yes	Yes
Year Fixed Effects	Yes	Yes	Yes	Yes
R^2	0.072	0.104	0.199	0.171
N	2945	2945	1557	1557

Notes: *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$. Dependent variable: $\ln p_{jt}$. Data: Analysis Sample, limited to observations with non-missing PMSOI. “Private Market Share of Older Individuals” is created for each HCPCS-year as the total revenue for the older age category (age 56 to 64) over the total revenue for the older and younger (26 to 44 years old) age categories summed. Robust standard errors clustered at the HCPCS level.

Table A2: Descriptive Statistics, Split By Private Market Share of Older Individuals

	Full Sample		Above Median PMSOI	Below Median PMSOI
	Mean	Std Dev	Mean	Mean
Private Market Share of Older Individuals (PMSOI) at $\tau = 1$	0.591	0.326	0.866	0.319
Relative ASP at $\tau = 8$	1.041	0.293	1.022	1.059
Average Year of Introduction	2010.9	3.8	2011.3	2010.5
Compound Annual Growth Rate over first 6 years	0.0382	0.0933	0.0247	0.0505
Compound Quarterly Growth Rate over first 6 years	0.0086	0.0227	0.0053	0.0117
N (Unique HCPCS)	197		98	99

Notes: Source: Authors’ calculations from CMS Data 2006-2019 and aggregate Truven Marketscan spending by age. “Private Market Share of Older Individuals” (PMSOI) is created for each HCPCS-year as the total revenue for the older age category (age 56 to 64) over the total revenue for the older and younger (26 to 44 years old) age categories summed. Number of observations is lower than in the Analysis Sample due to missing data (HCPCS with no private spending). Median Private Market Share of Older Individuals at Launch = .69

Table A3: Private Market Share of Older Individuals (PMSOI) and Price Growth

	(1)	(2)
τ	0.020*** (0.005)	
$\tau \times \text{PMSOI}$	-0.021*** (0.006)	
$\tau > 12 = 1$		0.081** (0.033)
$\tau > 12 \times \text{Above Median PMSOI} = 1$		-0.134** (0.057)
Drug Fixed Effects	Yes	Yes
Year Fixed Effects	Yes	Yes
R^2	0.111	0.105
N	4080	4080


Notes: *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$. Dependent variable: $\ln p_{jt}$. Data: Analysis Sample. Robust standard errors clustered at the HCPCS level.

Table A4: Effect of MMS on launch price

	(1)	(2)	(3)	(4)
	Weighted		Unweighted	
MMS	2.650*** (0.875)		1.021 (0.729)	
Above Median MMS		0.639 (0.449)		0.503 (0.349)
Drug FE	No	No	No	No
Year FE	Yes	Yes	Yes	Yes
τ FE	Yes	Yes	Yes	Yes
τ FE \times MMS	Yes	No	Yes	No
τ FE \times Above Median MMS	No	Yes	No	Yes
R-squared	0.220	0.060	0.020	0.020
N	4502	4502	4502	4508

Notes: *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$. Dependent variable: $\ln p_{jt}$. Data: Analysis Sample. Robust standard errors clustered at the HCPCS level.


Figure A1: Medicare Quantity Sold, Relative to Launch Period



Notes: Data: Analysis Sample. Quantity in each quarter is calculated as total Medicare revenue divided by ASP. Relative quantity is quantity in quarter τ divided by quantity in quarter $\tau = 1$. Relative quantity is winsorized at the 1st and 99th percentiles due to outliers. Plots the results of a regression of relative quantity against quarter τ fixed effects and year-quarter fixed effects weighted by total drug market size. Point estimates and 95% confidence intervals of the quarter τ fixed effects are present. Standard errors clustered at the HCPCS level.


Note that 2 years after launch, median quantity sold is very similar to quantity at launch (relative quantity=0.99), while the 99th percentile of relative quantity is over 20. This accounts for the jump in standard errors in the figure beginning 2 years after launch.

Figure A2: Distribution of MMS at Launch




Notes: Data: Analysis Sample

Figure A3: Time Until Competitor Entry in Billing Code




Notes: Plots Kaplan-Meier survivor function for being billing code monopolist split by above versus below median Medicare market share. Early entry due in part to new J-Codes that have old products. In Cox proportional hazard model, above median MMS products are more likely to have entry, but this difference is not statistically significant (Hazard ratio 0.975, 95% CI 0.54 to 1.75). Data: Analysis Sample.

Figure A4: Time Until Competitor Entry in Billing Code: Sample of Newly Approved Molecules




Notes: Plots Kaplan-Meier survivor function for being billing code monopolist.

Figure A5: Robustness Checks




Notes: Plots point estimates and 95% confidence intervals for coefficients from four different estimators. OLS is estimated by regression Equation 4 in which treatment is discretized into above versus below median MMS. Then, results from three additional two-way fixed effects estimators are presented: Callaway and Sant'Anna (2021), Chaisemartin and d'Haultfoeuille (2020) and Sun and Abraham (2021). Data: Analysis Sample. Robust standard errors clustered at the HCPCS level.

Figure A6: Robustness Checks



Notes: Plots point estimates and 95% confidence intervals for coefficients estimated by regression Equation 4. Data: Analysis Sample with modifications as shown in each subfigure's title. Robust standard errors clustered at the HCPCS level.

Figure A7: Additional Robustness Checks



Notes: Plots point estimates and 95% confidence intervals for coefficients estimated by regression Equation 4. Data: Analysis Sample, with modifications as follows. Main Figure recreates the estimates of Figure 2 on a common axis for reference. Results “Without Initial Cohort” estimates the effects without the earliest (and largest) treatment cohort (7.9% of observations). Results “Without Small Cohorts” estimates the effects without cohorts of two or fewer products (3.8% of observations). Results “Without Products Missing Data” estimates the effects without products which are missing any quarter of data (6.8% of observations). Robust standard errors clustered at the HCPCS level.